Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction

Many approaches to identify therapeutically relevant neoantigens couple tumor sequencing with bioinformatic algorithms and inferred rules of tumor epitope immunogenicity. However, there are no reference data to compare these approaches, and the parameters governing tumor epitope immunogenicity remai...

Full description

Saved in:
Bibliographic Details
Published inCell Vol. 183; no. 3; pp. 818 - 834.e13
Main Authors Wells, Daniel K., Dang, Kristen K., Sheehan, Kathleen C.F., Campbell, Katie M., Lamb, Andrew, Ward, Jeffrey P., Sidney, John, Blazquez, Ana B., Rech, Andrew J., Zaretsky, Jesse M., Ng, Alphonsus H.C., Yu, Thomas V., Manning, Patrice, Steiner, Gabriela M., Khan, Aly A., Lugade, Amit, Frentzen, Angela A. Elizabeth, Tadmor, Arbel D., Sasson, Ariella S., Rao, Arjun A., Pei, Baikang, Schrörs, Barbara, Peters, Bjoern, Li, Bo, Stevenson, Brian J., Iseli, Christian, Morehouse, Christopher A., Melief, Cornelis J.M., Puig-Saus, Cristina, van Beek, Daphne, Balli, David, Gfeller, David, Haussler, David, Jäger, Dirk, Cortes, Eduardo, Esaulova, Ekaterina, Sherafat, Elham, Bartha, Gabor, Liu, Geng, Coukos, George, Xenarios, Ioannis, Mandoiu, Ion, Kooi, Irsan, Kessler, Jan H., Greenbaum, Jason A., Perera, Jason F., Harris, Jason, Hundal, Jasreet, Shelton, Jennifer M., Wang, Jianmin, Wang, Jiaqian, Szustakowski, Joseph, Kodysh, Julia, Forman, Juliet, Wei, Lei, Lee, Leo J., Slagter, Maarten, Mueller, Markus, Lower, Martin, Vormehr, Mathias, Artyomov, Maxim N., Yang, Naibo, Raicevic, Nevena M. Ilic, Guex, Nicolas, Robine, Nicolas, Halama, Niels, Skundric, Nikola M., Milicevic, Ognjen S., Gellert, Pascal, Jongeneel, Patrick, Charoentong, Pornpimol, Tanden, Prateek, Hu, Qiang, Gupta, Ravi, Petit, Robert, Ziman, Robert, Hilker, Rolf, Shukla, Sachet A., Boyle, Sean M., Qiu, Si, Salama, Sofie, Liu, Song, Wu, Song, Ketelaars, Steven L.C., Jhunjhunwala, Suchit, Shcheglova, Tatiana, Schuepbach, Thierry, Creasy, Todd H., Kovacevic, Vladimir B., Krebber, Willem-Jan, Sebastian, Yinong, Yalcin, Zeynep Kosaloglu, Selinsky, Cheryl, Ribas, Antoni, Hellmann, Matthew D., Hacohen, Nir, Sette, Alessandro, Heath, James R., Schreiber, Robert D., Kvistborg, Pia
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 29.10.2020
Subjects
Online AccessGet full text
ISSN0092-8674
1097-4172
1097-4172
DOI10.1016/j.cell.2020.09.015

Cover

More Information
Summary:Many approaches to identify therapeutically relevant neoantigens couple tumor sequencing with bioinformatic algorithms and inferred rules of tumor epitope immunogenicity. However, there are no reference data to compare these approaches, and the parameters governing tumor epitope immunogenicity remain unclear. Here, we assembled a global consortium wherein each participant predicted immunogenic epitopes from shared tumor sequencing data. 608 epitopes were subsequently assessed for T cell binding in patient-matched samples. By integrating peptide features associated with presentation and recognition, we developed a model of tumor epitope immunogenicity that filtered out 98% of non-immunogenic peptides with a precision above 0.70. Pipelines prioritizing model features had superior performance, and pipeline alterations leveraging them improved prediction performance. These findings were validated in an independent cohort of 310 epitopes prioritized from tumor sequencing data and assessed for T cell binding. This data resource enables identification of parameters underlying effective anti-tumor immunity and is available to the research community. [Display omitted] •Diverse neoantigen predictions on shared genomic data from a global consortium•37 out of 608 tested peptide-MHCs are bound by patient-matched T cells•Epitope presentation and recognition characteristics predict immunogenicity•Model-based interventions improve neoantigen prediction Genomic tumor sequencing data with matched measurements of tumor epitope immunogenicity allows for insights into the governing parameters of epitope immunogenicity and generation of models for effective neoantigen prediction.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
AUTHOR CONTRIBUTIONS
Conceptualization, V.M.H.-L., A.K., J.G., F.R., and R.D.S.; Methodology, D.K.W., N.A.D., K.K.D., J.G., A.K., N.H., A.S., J.R.H., N.B., F.R., R.D.S., T.N.S., and P.K.; Software, D.K.W., K.K.D., A.L., A.J.R., T.V.Y., X.C.D., and the Tumor Neoantigen Selection Alliance; Validation, M.M.v.B., T.N.S., and P.K.; Formal Analysis: D.K.W. and K.K.D.; Investigation: D.K.W., N.A.D., M.M.v.B., K.K.D., K.C.F.S., K.M.C., J.P.W., J.S., A.B.B., B.C.-A., A.H.C.N., W.C., G.M.S., and the Tumor Neoantigen Selection Alliance; Resources, K.K.D., K.C.F.S., A.L., J.P.W., A.J.R., J.M.Z., B.C-A., T.V.Y., H.R., J.M.C., P.M., the Tumor Neoantigen Selection Alliance, T.M., J.G., C.S., A.R., M.D.H., A.S., J.R.H., N.B., R.D.S., T.N.S., and P.K.S.; Data Curation, D.K.W., N.A.D., M.M.v.B., K.K.D., K.C.F.S., A.L., T.V.Y., H.R., J.M.C., and P.K.; Writing – Original Draft, D.K.W. and N.A.D.; Writing – Review & Editing, D.K.W., N.A.D., M.M.v.B., K.K.D., V.M.H.-L., K.C.F.S., M.D.H., N.H., F.R., R.D.S., T.N.S., and P.K.; Visualization, D.K.W. and N.A.D.; Supervision, N.A.D., D.K.W., M.M.v.B., K.K.D., K.C.F.S.,T.M., J.G., C.S., A.R., M.D.H., N.H., A.S., J.R.H., N.B., F.R., R.D.S., T.N.S., and P.K.; Project Administration, N.A.D., D.K.W., K.K.D., C.S., F.R., and P.K.
ISSN:0092-8674
1097-4172
1097-4172
DOI:10.1016/j.cell.2020.09.015